Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Current Deferred Revenue (2017 - 2020)

Serina Therapeutics (SER) has disclosed Current Deferred Revenue for 4 consecutive years, with $275000.0 as the latest value for Q4 2020.

  • Quarterly Current Deferred Revenue fell 2.83% to $275000.0 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $275000.0 through Dec 2020, down 2.83% year-over-year, with the annual reading at $275000.0 for FY2020, 2.83% down from the prior year.
  • Current Deferred Revenue hit $275000.0 in Q4 2020 for Serina Therapeutics, up from $255000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $407000.0 in Q1 2020 to a low of $180000.0 in Q4 2017.
  • Historically, Current Deferred Revenue has averaged $281111.1 across 4 years, with a median of $275000.0 in 2020.
  • Biggest five-year swings in Current Deferred Revenue: soared 76.11% in 2018 and later fell 10.73% in 2019.
  • Year by year, Current Deferred Revenue stood at $180000.0 in 2017, then skyrocketed by 76.11% to $317000.0 in 2018, then dropped by 10.73% to $283000.0 in 2019, then dropped by 2.83% to $275000.0 in 2020.
  • Business Quant data shows Current Deferred Revenue for SER at $275000.0 in Q4 2020, $255000.0 in Q3 2020, and $328000.0 in Q2 2020.